RE:CMO presenting “Presentation
SORT1+ TechnologyTM Platform & Novel Peptide Drug Conjugates (PDC’s) Targeting Sortilin (SORT1) Positive Cancers
Sortilin (SORT1) is an emerging biomarker/target in cancer expressed in many solid tumors. This presentation will include a discussion of a unique MOA facilitating rapid internalization of PDC’s carrying less toxic payloads into cancer cells, with improved efficacy/safety profiles, preclinical data, update on ph1 trial and future development potential of this novel SORT1+ platform.”
These are the topics which will be discussed now would that update will be initiating basket trial or more specific information?
And what are the potentials? We already know RNA, SN-38 conjugates have been mentioned/considered and possibly explored although for now it would be early ongoing preclinical stages.
This event is pay per view! Would it be nice to arrange similar events free for investors?